UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Blood cancer journal (New York), 2019-03, Vol.9 (4), p.37-37, Article 37

2019

Volltextzugriff (PDF)

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Blood, 2014-10, Vol.124 (14), p.2190-2195

2014

Volltextzugriff (PDF)

Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells

Proceedings of the National Academy of Sciences - PNAS, 2012-10, Vol.109 (43), p.17573-17578

2012

Volltextzugriff (PDF)

MicroRNA expression in maturing murine megakaryocytes

Blood, 2010-12, Vol.116 (23), p.e128-e138

2010

Volltextzugriff (PDF)

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

The lancet oncology, 2018-12, Vol.19 (12), p.1641-1653

2018

Volltextzugriff (PDF)

Nucleic-acid therapeutics: basic principles and recent applications

Nature reviews. Drug discovery, 2002-07, Vol.1 (7), p.503-514

2002

Volltextzugriff (PDF)

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

Investigational new drugs, 2018-12, Vol.36 (6), p.1016-1025

2018

Volltextzugriff (PDF)

Trisomy 21 enhances human fetal erythro-megakaryocytic development

Blood, 2008-12, Vol.112 (12), p.4503-4506

2008

Volltextzugriff (PDF)

Multigene Targeting with Antisense Oligodeoxynucleotides: An Exploratory Study Using Primary Human Leukemia Cells

Clinical cancer research, 2005-07, Vol.11 (13), p.4948-4954

2005

Volltextzugriff (PDF)

Nucleic Acid Therapeutics for Hematologic Malignancies-Theoretical Considerations

Annals of the New York Academy of Sciences, 2006-10, Vol.1082 (1), p.124-136

2006

Volltextzugriff (PDF)

Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules

Nucleic acids research, 2005-01, Vol.33 (3), p.e28-e28

2005

Volltextzugriff (PDF)

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Blood, 2016-12, Vol.128 (22), p.1148-1148

2016

Volltextzugriff (PDF)

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Blood, 2011-11, Vol.118 (21), p.1856-1856

2011

Volltextzugriff (PDF)

Nucleic acid therapeutics: a work in progress

Current opinion in investigational drugs (London, England : 2000), 2002-06, Vol.3 (6), p.928

2002

Volltextzugriff (PDF)

Downregulation of Ribosomal Proteins Is Seen in Non 5q- MDS

Blood, 2008-11, Vol.112 (11), p.854-854

2008

Volltextzugriff (PDF)

Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes

Blood, 2008-11, Vol.112 (11), p.595-595

2008

Volltextzugriff (PDF)

Trisomy 21 enhances human fetal erythro-megakaryocytic development. Commentary

Blood, 2008, Vol.112 (12)

2008

Volltextzugriff (PDF)

Therapeutic potential of antisense nucleic acid molecules

Science's signal transduction knowledge environment (STKE), 2003-10, Vol.2003 (206), p.pe47

2003

Volltextzugriff (PDF)

Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis

PLoS genetics, 2011-03, Vol.7 (3), p.e1001356

2011

Volltextzugriff (PDF)

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

Journal of the advanced practitioner in oncology, 2023-09, Vol.14 (6), p.503-518

2023

Volltextzugriff (PDF)

Correction: Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis

PLoS genetics, 2011-05, Vol.7 (5)

2011

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Science & Technology
(12)
Life Sciences & Biomedicine
(11)
Female
(5)
Hematology
(5)
Animals
(4)
Male
(4)
Oligonucleotides, Antisense - Therapeutic Use
(4)
Oncology
(4)
Adult
(3)
Aged
(3)
Dose-Response Relationship, Drug
(3)
Gene Expression Profiling
(3)
Middle Aged
(3)
Multiple Myeloma - Drug Therapy
(3)
Patients
(3)
Pharmacology & Pharmacy
(3)
Time Factors
(3)
Administration, Oral
(2)
Aged, 80 And Over
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells

MicroRNA expression in maturing murine megakaryocytes

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Nucleic-acid therapeutics: basic principles and recent applications

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

Trisomy 21 enhances human fetal erythro-megakaryocytic development

Multigene Targeting with Antisense Oligodeoxynucleotides: An Exploratory Study Using Primary Human Leukemia Cells

Nucleic Acid Therapeutics for Hematologic Malignancies-Theoretical Considerations

Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Nucleic acid therapeutics: a work in progress

Downregulation of Ribosomal Proteins Is Seen in Non 5q- MDS

Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes

Trisomy 21 enhances human fetal erythro-megakaryocytic development. Commentary

Therapeutic potential of antisense nucleic acid molecules

Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

Correction: Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis

Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis: e1001356

Correction: Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis

Suchergebnisse filtern